No Data
[Hong Kong Stock Connect] INNOCARE (09969) rises over 9%. The clinical phase II results of orelizumab for treating RRMS show high effectiveness and safety.
Jingwu Financial News | INNOCARE (09969) stock price fluctuates upwards, currently reported at HKD 9.8, an increase of 9.38%, with a trading volume of HKD 0.339 billion. In terms of news, the company announced that its new BTK inhibitor, Orelabrutinib, has shown high efficacy and safety in the Phase II clinical trial for treating relapsing-remitting multiple sclerosis (RRMS). An 80 mg daily dose of Orelabrutinib has been determined for the Phase III clinical trial. At week 12, all three dose groups of Orelabrutinib showed a reduction in cumulative new Gd+T1 lesions in the brain compared to the placebo group.
InnoCare Pharma Anti-MS Drug Selected for Phase 3 Studies Following Efficacy, Safety Results
INNOCARE (688428.SH): Released phase II clinical data for the new BTK inhibitor, Orelabrutinib, at the forum.
INNOCARE (688428.SH) announced that the company will participate in the 10th Americas Multiple Sclerosis Treatment in 2025...
INNOCARE (688428.SH): Released Phase II clinical data on the use of Obtobrutinib for the treatment of relapsing-remitting multiple sclerosis at the 10th Annual Forum of the Americas Committee for Multiple Sclerosis Treatment and Research.
On February 26, Gelonghui reported that INNOCARE (688428.SH) announced that at the 10th Annual Forum of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) in 2025, new phase II clinical data for the novel BTK inhibitor Obeticholic Acid in the treatment of relapsing-remitting multiple sclerosis (referred to as 'RRMS') will be presented, with a live poster display scheduled for February 27 at Eastern Time (Poster Code: P094). The study results indicate that Obeticholic Acid demonstrates high efficacy in treating RRMS patients. A daily dose of 80 mg of Obeticholic Acid shows optimal effectiveness and
Pharmaceutical stocks generally rose, with KCP Pharmaceutical (02171) increasing by 25.29%. Institutions expect that after the first quarter report, the pharmaceutical Sector is likely to see an overall performance reversal in the Industry.
Jinwu Financial News | Pharmaceutical stocks have generally risen, with Keji Pharmaceutical (02171) up 25.29%, INNOCARE (09969) up 14.58%, REMEGEN (09995) up 12.88%, Yiming Anke (01541) up 12.25%, Lepu Biopharma (02157) up 10.67%, YSB (09885) up 6.88%, and Gushengtang (02273) up 6.71%. The Hong Kong stock Pharmaceutical ETF has risen 3.59%, and the Hong Kong Stock Connect Yinhua CSI Innovative Drugs Industry ETF has risen 4.05%. Ping An Securities stated that on January 17, 2025, the National Healthcare Security Administration will hold a '
InnoCare Pharma's ICP-248 Combo Therapy Approved for Phase III Trial
